Treatment of High-Risk Neuroblastoma

被引：11
|
作者：
Krystal, Julie [1 ]
Foster, Jennifer H. [2 ]
机构：
[1] Cohen Childrens Med Ctr, Zucker Hofstra Sch Med, Dept Pediat, New Hyde Pk, NY 11040 USA
[2] Texas Childrens Canc Ctr, Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA
来源：
CHILDREN-BASEL | 2023年 / 10卷 / 08期
关键词：
neuroblastoma; pediatric oncology; solid tumor; OPEN-LABEL; CLASSIFICATION-SYSTEM; PROGNOSTIC IMPACT; CHILDHOOD-CANCER; FREE SURVIVAL; LOCAL-CONTROL; COG A3973; PHASE-II; CHILDREN; CHEMOTHERAPY;
D O I：
10.3390/children10081302
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
High-risk neuroblastoma is a highly aggressive solid tumor that most commonly presents in early childhood. Advances in treatment through decades of clinical trials and research have led to improved outcomes. This review provides an overview of the current state of treatment for high-risk neuroblastoma.
引用
收藏
页数：11
相关论文
共 50 条
  • [41] Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy
    Keyel, Michelle E.
    Reynolds, C. Patrick
    BIOLOGICS-TARGETS & THERAPY, 2019, 13 : 1 - 12
  • [42] Treatment of high-risk neuroblastoma with anti-GD2 antibodies
    Castel, Victoria
    Segura, Vanessa
    Canete, Adela
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2010, 12 (12): : 788 - 793
  • [43] The Role of 131I-MIBG in High-Risk Neuroblastoma Treatment
    Lessig, Megan Kinnear
    JOURNAL OF PEDIATRIC ONCOLOGY NURSING, 2009, 26 (04) : 208 - 216
  • [44] Outcomes After Proton Therapy for Treatment of Pediatric High-Risk Neuroblastoma
    Hill-Kayser, Christine E.
    Tochner, Zelig
    Li, Yimei
    Kurtz, Goldie
    Lustig, Robert A.
    James, Paul
    Balamuth, Naomi
    Womer, Richard
    Mattei, Peter
    Grupp, Stephen
    Mosse, Yael P.
    Maris, John M.
    Bagatell, Rochelle
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (02): : 401 - 408
  • [45] RESULTS OF TREATMENT OF PATIENTS WITH NEUROBLASTOMA STAGE 3 HIGH-RISK GROUPS
    Hizhnikov, A.
    Anatoly, K.
    Polad, K.
    Michael, R.
    Marina, R.
    Olga, K.
    Diana, R.
    PEDIATRIC BLOOD & CANCER, 2015, 62 : S330 - S330
  • [46] Dinutuximab: A Novel Immunotherapy in the Treatment of Pediatric Patients With High-Risk Neuroblastoma
    Bartholomew, Joy
    Washington, Tanea
    Bergeron, Sharon
    Nielson, Danelle
    Saggio, Jennifer
    Quirk, Lindsay
    JOURNAL OF PEDIATRIC ONCOLOGY NURSING, 2017, 34 (01) : 5 - 12
  • [47] Surgical challenges associated with intensive treatment protocols for high-risk neuroblastoma
    Cantos, Mae F.
    Gerstle, J. Ted
    Irwin, Meredith S.
    Pappo, Alberto
    Farley, Shannon
    Cheang, Timothy
    Kim, Peter C. W.
    JOURNAL OF PEDIATRIC SURGERY, 2006, 41 (05) : 960 - 965
  • [48] Treatment of high-risk neuroblastoma with anti-GD2 antibodies
    Victoria Castel
    Vanessa Segura
    Adela Cañete
    Clinical and Translational Oncology, 2010, 12 : 788 - 793
  • [49] Treatment of High-Risk Neuroblastoma in a Southeast Asian Hub of Medical Tourism
    Lee, A.
    Chui, C. H.
    Aung, L.
    Wong, W.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S263 - S263
  • [50] Integrative discovery of treatments for high-risk neuroblastoma
    Elin Almstedt
    Ramy Elgendy
    Neda Hekmati
    Emil Rosén
    Caroline Wärn
    Thale Kristin Olsen
    Cecilia Dyberg
    Milena Doroszko
    Ida Larsson
    Anders Sundström
    Marie Arsenian Henriksson
    Sven Påhlman
    Daniel Bexell
    Michael Vanlandewijck
    Per Kogner
    Rebecka Jörnsten
    Cecilia Krona
    Sven Nelander
    Nature Communications, 11
12345